Abstract: Embodiments of the present systems and methods may provide techniques to predict the success or failure of a drug used for disease treatment. For example, a method of determining drug efficacy may include, for a plurality of patients, generating a directed acyclic graph from health related information of each patient comprising nodes representing a medical event of the patient, at least one first edge connecting the first node to an additional node, each additional edge connecting nodes representing two consecutive medical events, the edge having a weight based on a time difference between the two consecutive medical events, capturing a plurality of features from each directed acyclic graph, generating a binary graph classification model on captured features of each directed acyclic graph, determining a probability that a drug or treatment will be effective using the binary graph classification model, and determining a drug to be prescribed to a patient based on the determined probability.

Abstract: Technologies are provided for efficiently querying a database using a plurality of oblivious random-access memories (ORAMs) while providing differential privacy. Subsets of a set of database records can be stored in a plurality of ORAMs. The subsets of database records in the separate ORAMs can be concurrently accessed (for example, by a database query server). When a database query is received, a number of database records that match the query can be identified for each of the ORAMs. A differential privacy constraint can be used to determine an additional number of database records to be retrieved from each ORAM. The differential privacy constraint can specify an upper bound on the number of records to be retrieved from each ORAM to prevent (or reduce the risk of) information leakage. Once all of the identified records are retrieved from the plurality of ORAMs, the additional records can be discarded.

Abstract: A system for carrying out electrochemical nuclear magnetic resonance spectroscopy (EC-NMR) is disclosed, along with methods of manufacturing the EC-NMR system, and methods of using the EC-NMR system to monitor electrochemical reactions. The system comprises interdigitated electrodes arranged in a cylindrically symmetric manner. The system allows for nuclear magnetic resonance spectroscopy to be carried out on a sample during electrolysis with minimal effect to its sensitivity.

Abstract: A method for training vibrotactile speech perception in the absence of auditory speech can comprise selecting a first word, generating a first control signal configured to cause at least one vibrotactile transducer to vibrate against a person's body with a first vibration pattern based on the first word, sampling a second word spoken by the person, generating a second control signal configured to cause at least one vibrotactile transducer to vibrate against the person's body with a second vibration pattern based on the sampled second word, and presenting a comparison between the first word and the second word to the person. An array of vibrotactile transducers can be in contact with the person's body.

Abstract: The present invention relates to assays, methods, and kits to assess traumatic brain injury (TBI) in a subject. The present invention also relates to ultrasensitive assays for GFAP, tau, CKBB, IL-1?, IL-2, IL-6, IL-10, IL-22, IP-10, TNF?, TSLP, NFL, and/or NFH.

Abstract: In certain aspects, the invention relates to methods of treating proliferative cervical disorders (such as cervical cancer and cervical dysplasia) and treating virus infection by administering artemisinin-related compounds. In certain aspects, the invention relates to methods of treating a tumor induced by an oncogenic virus, methods of killing or inhibiting a squamous cell carcinoma, and methods of inhibiting the replication of a virus, by administering artemisinin-related compounds.

Abstract: Described herein are methods of predicting drug-target interactions and methods of using the information for drug repurposing. The methods described herein combine different descriptors, including, for example, atom pair similarity, shape, topology and chemical signatures, physico-chemical functional descriptors, contact points of the ligand and the target protein, chemical similarity, and docking score.

Abstract: A triage system that determines whether a user is likely to have contracted a disease based on sensor data received from a user device (e.g., a smartphone or activity tracker). Each symptom is identified by comparing sensor data to a predetermined baseline and comparing the difference to a predetermined symptom threshold. Because direct measurement of symptoms using the sensors available to the user may not be feasible or sufficiently accurate, the triage system also uses surrogates the identify certain symptoms. For example, a fever may be identified using heart data, a cough or shortness of breath may be identified by analyzing recorded sound, fatigue may be identified by analyzing the movement of the user device, and loss of smell or taste may be identified by recording sound and using speech detection algorithms to identify phrases in the recorded sound indicative of loss of smell or taste.

Abstract: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.

Abstract: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's proteomic profile and comparing the value of the subject's proteomic profile with the value of a normal proteomic profile. A change in the value of the subject's proteomic profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.

Abstract: The present invention is directed to analytical methods for determining the concentration, and/or stereoisomeric excess, and/or absolute configuration of chiral analytes in a sample.

Abstract: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.

Abstract: Provided are methods, kits, and systems useful in the performance of analysis and reporting of highly polymorphic loci, including, in particular, the performance of analysis and reporting of HLA typing. Combining one-step sequencing and sequence-specific oligonucleotide probe hybridization, the methods, kits, and systems offer improved efficiency of HLA typing while providing detailed sequencing information. In certain embodiments the methods and systems comprise one or more software applications to facilitate data acquisition, processing, and reporting.

Abstract: Provided are batteries and fuel cells incorporating a stripline detector for use in nuclear magnetic resonance (NMR). The stripline batteries and fuel cells can be used for in situ NMR measurement of battery or fuel cell chemistry. Also provided are methods for measuring in situ battery and fuel cell NMR using the stripline batteries and fuel cells of the invention.

Abstract: Provided herein are methods of treating or preventing a neurodegenerative disease, a myodegenerative disease or a prion disease in a subject comprising administering a tyrosine kinase inhibitor.

Abstract: A system and method for connecting one or more client applications with one or more knowledge representation servers and communicating there between includes an application programming interface (API) and a hypergraph transfer protocol (HGTP), for facilitating communication between the one or more client applications and one or more knowledge representation servers responsive to a client application request. The client application request includes an API call for a specific entity that is received by a first knowledge representation server. If the first knowledge representation server does not manage the specific entity, the first knowledge representation server forwards the specific entity call to a second knowledge representation server via the HGTP using a universal unique identifier (UUID) associated with the specific entity having encoded therein a network address for the second knowledge representation server.

Abstract: Provided herein are methods for treating a cholecystokinin (CCK) receptor-expressing cancerous tumor in a subject. Also provided are methods for increasing sensitivity of a (CCK) receptor-expressing cancerous tumor in a subject to immunotherapy.

Abstract: Compositions comprising bile acids or their salts and methods of use thereof for the treatment of residual lesions of vascular anomalies.

Abstract: Provided herein are methods for detecting a cerebrospinal fluid-specific (CSF-specific) glycoform of Apolipoprotein E (APOE) in a subject.

Abstract: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise determining the influx of polyunsaturated fatty acids (PUFAs) into the brain from plasma in a test subject and comparing this measured influx to a normal standard influx. An increase in influx of PUFAs from the plasma into the brain is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.